On July 31, Boston Scientific fell 3.13% in regular trading, trading at $44.555 per share, with turnover of $170 million.

On the news front, Argus downgraded Boston Scientific from Buy to Hold, marking the first outright rating downgrade since the company's Q2 earnings release. On the same day, Oppenheimer flagged that the Watchman business slowdown raises utilization questions, with the gap versus initial long-range targets widening into 2027.

The core drag remains the Watchman cardiac occluder device. Management expects second-half Watchman revenue to decline mid-to-high single digits year-over-year, as physicians increasingly combine Watchman procedures with other cardiac surgeries, reducing standalone procedure volumes. Multiple investment banks had already cut price targets in prior sessions — UBS to $67, Deutsche Bank to $60, RBC to $70, and Piper Sandler to $60 — though all maintained Buy ratings. The Argus downgrade to Hold further intensified bearish market sentiment, extending a three-day post-earnings selloff.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)